Related coverage linked through entity extraction aliases.
May 05, 2026
The United Arab Emirates has unveiled two gene therapy projects targeting autism, epilepsy, and rare brain disorders in children. The initiatives focus on underlying genetic causes and earlier diagnosis.
Apr 16, 2026
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
Apr 01, 2026
A study finds most children with enterovirus meningitis have favorable long-term outcomes, with only 8.9% experiencing adverse sequelae. Meanwhile, global data shows 259,000 meningitis deaths in 2023, with children under 5 accounting for over one-third of fatalities. Non-polio enteroviruses were the leading cause of meningitis cases worldwide.
Mar 18, 2026
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
Mar 14, 2026
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
Mar 04, 2026
Amylyx Pharmaceuticals is advancing avexitide toward potential FDA approval for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial results expected in Q3 2026 and a cash runway extending into 2028.
Feb 25, 2026
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
Feb 24, 2026
The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.
Feb 24, 2026
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
Feb 19, 2026
The U.S. Food and Drug Administration issued two Emergency Use Authorizations on February 18, 2026, for NexGard products to treat New World screwworm infestations in dogs and cats.
Feb 16, 2026
Researchers at Monash University have identified DNA sequence variations in mothers that modify the risk of birth defects from valproic acid, an anti-seizure medication, paving the way for a genetic test to identify who can safely take the drug during pregnancy.
Oct 01, 2025
The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.
